|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||82.74 - 83.08|
|52-week range||55.69 - 86.31|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||79.92|
|Forward dividend & yield||0.33 (0.40%)|
|Ex-dividend date||10 May 2021|
|1y target est||N/A|
By Dhirendra Tripathi
ZURICH (Reuters) -Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year. "In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters. Its previous guidance had been for sales growth in the low double-digit range.
Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.